You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Boston-based firm is pursuing nanopore technology as a readout for its unique information-encoding format, which could help customers store vast amounts of data.
UK-based ATDBio will develop new oligonucleotide-tagged microbeads for use in droplet-based single-cell RNA sequencing, to be evaluated by researchers at Oxford.
The Bay Area DNA synthesis company said it was "not significantly affected" by the COVID-19 pandemic and beat Wall Street revenue estimates.
The firm added $50 million from Casdin Capital, Danaher Life Sciences, and Agilent Technologies to its $38.5M Series B round announced in May 2019.
The firm is offering approximately 3 million shares and said it may use a portion of the proceeds to acquire, license, or invest in complementary businesses or products.
The synthetic biology firm had total revenues of $19.3 million and withdrew its financial guidance for fiscal year 2020 citing uncertainty caused by COVID-19.
The Cambridge, UK-based gene synthesis firm plans to use the funds to accelerate development of its silicon platform and introduce a desktop device.
The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.
The company booked a net loss of $55.6 million, or $1.69 per share, for the quarter which included litigation settlement expenses of $22.5 million.
A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.